Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer Post author: Post published:January 27, 2024 Post category:uncategorized Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. You Might Also Like Coronary artery calcium scoring with CT can predict risk of heart attacks or strokes March 5, 2024 Fluorescent bacteria enable real-time tumor visualization during surgery July 21, 2025 Many Americans turn to AI for health answers despite accuracy warnings July 14, 2025